UAE’s Neopharma and ASKA of Japan to build drug plant in India in $53M JV

Taj mahal on a bright day in Agra, India
UAE-based drugmaker Neopharma and ASKA Pharma of Tokyo will build a $53 million pharmaceutical manufacturing facility in India. (Somchaisom/Getty Images)

United Arab Emirates-based drugmaker Neopharma and ASKA Pharmaceuticals of Tokyo entered a joint venture to build a $53 million (₹350-crore) pharmaceutical manufacturing facility to be operated by Neopharma subsidiary Omnicare Drugs India in Visakhapatnam.

The plant is expected to open by 2020 and will produce oral solid dosage forms, oral liquids and topical preparations. The capacity of the facility is projected at 3 billion tablets a year, The Hindu reported.

The joint venture aims to manufacture drugs for chronic therapies in cardiovascular diseases, the central nervous system and diabetes, along with other products from key therapeutic classes targeting Japan and the world market.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Construction is set to begin this month at a site in J.N. Pharma City. The company said it will seek cGMP accreditation from all major global health regulatory bodies.

"The partnership will enable us to transfer skills and knowledge locally," B.R. Shetty, Neopharma’s chairman, said in a statement.

Last summer, Neopharma announced it would build a $100 million plant in Abu Dhabi. That news came just weeks after the drugmaker said it would spend more than twice that for manufacturing plant and development rights to a diabetes treatment in Japan.

Suggested Articles

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.

The FDA has come down on a small U.S. drugmaker for taking a skin medication to market even though there were out-of-spec test results at release.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.